I agree with your purpose, however, what you conclude was not proven: non-inferiority. Furthermore, the tox differences did not result in less treatment adherence – in contrast more patients did not adhere to the protocol in the weekly arm. The same held true for GOG study not showing superiority – and the ICON 8 as well – and all studies except the MITO study showed more (!) toxicity with the weekly regimen. It is more uncomfortable with more need of doctor appointments and more expensive.

However, this is all not so extremely important and I could agree that we include the MITO regimen as option for patients – but are we willing to change practice based on a trial with MITO as standard arm? – and this is the question (and not clinical routine for selected patients).